Novel use of low-dose cidofovir (2.5 mg/kg Weekly) as CMV prophylaxis in the pre-engraftment Phase of stem cell transplantation: A viable alternative when ganciclovir is contraindicated and letermovir is not available

Vistide (cidofovir) - Gilead

Cytovene (ganciclovir) - Roche

Prevymis (letermovir) - Merck (MSD)

cyclophosphamide - Generic mfg.

Santanu Sen; Nirali Sanghvi; Manam Mehra; Shyla Sen; Tanu Singhal

Dec 5, 2025